Noticias y Actividades de Travere Therapeutics
Presencia
Travere Therapeutics es una de las ...
Travere Therapeutics es una empresa que cotiza bajo el símbolo de cotización TVTX (US).
Ejecutivos
Ver el organigrama con sus 34 ejecutivos principales
Biografías más buscadas en Travere Therapeutics
- Eric Dube, Director, President and Chief Executive Officer
- Gary Lyons, Independent Chairman of the Board
- Tim Coughlin, Director
Recientes movimientos de ejecutivos en Travere Therapeutics
- Leah Conley que ha sido Vice President of Market Access, ha ascendido a Senior Vice President, Patient Access (noticia publicada el 26 de febrero de 2025).
- Jeremy Von Kuster que ha sido Director of Finance, ha ascendido a Senior Director of Financial Planning and Analysis (noticia publicada el 23 de agosto de 2024).
- Nivi Nehra que ha sido Vice President and Head of Corporate Communications, pasa a ser Vice President, Head of Corporate Communications and Investor Relations (noticia publicada el 23 de agosto de 2024).
Crear su alerta
para seguir los movimientos de los ejecutivos en Travere Therapeutics.
Biotecnología
Travere Therapeutics tiene 2.350 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnología
- Transcarent and Accolade have merged (publicado el 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 4 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Travere Therapeutics
- Travere Therapeutics Provides Corporate Update and 2025 Outlook | Travere Therapeutics, Inc.
- Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Travere Therapeutics, Inc.
- Travere Therapeutics to Present at Upcoming Investor Conferences | Travere Therapeutics, Inc.
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Travere Therapeutics, Inc.
- Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares | Travere Therapeutics, Inc.
- Travere Therapeutics Announces Proposed Public Offering of Common Stock | Travere Therapeutics, Inc.
- Travere Therapeutics to Present at Upcoming Investor Conferences | Travere Therapeutics, Inc.
- Travere Therapeutics Announces Pricing of Public Offering of Common Stock | Travere Therapeutics, Inc.
- Travere Therapeutics Reports Third Quarter 2024 Financial Results | Travere Therapeutics, Inc.
- Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 | Travere Therapeutics, Inc.
- View more press releases Close
Redes sociales sobre Travere Therapeutics
- Travere Therapeutics en Wikipedia, Google News y Yahoo Finance
- Travere Therapeutics en LinkedIn, Twitter y YouTube
